Two Sigma Advisers
GNMX

Two Sigma Advisers’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Two Sigma Advisers’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,100
Closed -$13K – 2416
2017
Q2 		$13K Sell
10,100
-2,100
-17% -$3.04K ﹤0.01% 2232
2017
Q1 		$23K Buy
+12,200
New +$55.2K ﹤0.01% 2321

Other funds holding GNMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCMW
Northern Capital Management (Wisconsin) Madison, Wisconsin $373M AUM 11.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Two Sigma Advisers's GNMX Position: Q3 2017 in Review

Two Sigma Advisers sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2017, closing a stake of 10,100 shares — an estimated $13K sold.

Two Sigma Advisers first reported a position in GNMX in Q1 2017 and held it in 2 quarters. The position peaked at $23K in Q1 2017. 49 funds tracked by Wall St. Rank hold GNMX as of Q3 2017.

  • Two Sigma Advisers reported no remaining Aevi Genomic Medicine Inc position as of Q3 2017 after selling out during the quarter.
  • Two Sigma Advisers sold 10,100 Aevi Genomic Medicine Inc shares in Q3 2017, an estimated $13K.
  • Two Sigma Advisers first reported a position in Aevi Genomic Medicine Inc in Q1 2017 and held it in 2 quarters.
  • Two Sigma Advisers's Aevi Genomic Medicine Inc position peaked at $23K in Q1 2017.
  • 49 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2017.

Based on Two Sigma Advisers's 13F filing for Q3 2017, filed 14 Nov 2017.